1. Home
  2. TYRA vs DCO Comparison

TYRA vs DCO Comparison

Compare TYRA & DCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

HOLD

Current Price

$28.28

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo Ducommun Incorporated

DCO

Ducommun Incorporated

HOLD

Current Price

$162.51

Market Cap

1.9B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
TYRA
DCO
Founded
2018
1849
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Military/Government/Technical
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.9B
IPO Year
2021
1995

Fundamental Metrics

Financial Performance
Metric
TYRA
DCO
Price
$28.28
$162.51
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
5
Target Price
$47.50
$153.60
AVG Volume (30 Days)
807.7K
178.7K
Earning Date
05-06-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.64
Revenue
N/A
$824,730,000.00
Revenue This Year
N/A
$7.40
Revenue Next Year
N/A
$8.59
P/E Ratio
N/A
$256.73
Revenue Growth
N/A
4.85
52 Week Low
$8.98
$80.12
52 Week High
$40.65
$168.74

Technical Indicators

Market Signals
Indicator
TYRA
DCO
Relative Strength Index (RSI) 42.75 66.02
Support Level $27.40 $135.11
Resistance Level $31.57 N/A
Average True Range (ATR) 1.98 6.19
MACD 0.26 0.93
Stochastic Oscillator 42.12 80.11

Price Performance

Historical Comparison
TYRA
DCO

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

About DCO Ducommun Incorporated

Ducommun Inc provides engineering & manufacturing services for high-performance products & high-cost-of failure applications used in the aerospace and defense, industrial, medical & other industries. The company's reportable segments are Structural Systems & Electronic Systems. Structural Systems designs, engineers and manufactures various sizes of complex contoured aerostructure components and assemblies and supplies composite and metal bonded structures and assemblies. Electronic Systems designs, engineers and manufactures high-reliability electronic and electromechanical products used in technology-driven markets including A&D and Industrial end-use markets. It generates maximum of its revenue from the Electronic Systems.

Share on Social Networks: